Drugs.com - Clinical Trials

Datopotamab Deruxtecan Granted Priority Review in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

13 January 2025 -- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or...

Feb 9, 2025 - 22:25
 0
Datopotamab Deruxtecan Granted Priority Review in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
13 January 2025 -- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or...
Read More

Tags:

Previous Article

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letet...

Next Article

GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227, Receives US FDA Breakthro...

Related Posts

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis

Nipocalimab Granted U.S. FDA Priority Review for the Tr...

Feb 9, 2025  0

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus

LimmaTech Awarded FDA Fast Track Designation for Vaccin...

Feb 9, 2025  0

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgagene Civaparvovec in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR ...

Feb 9, 2025  0